Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $87.3 million.

  • Iovance Biotherapeutics' Accumulated Expenses changed N/A to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year change of. This contributed to the annual value of $81.9 million for FY2024, which is 1805.32% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Accumulated Expenses stood at $87.3 million.
  • Iovance Biotherapeutics' Accumulated Expenses' 5-year high stood at $89.1 million during Q2 2025, with a 5-year trough of $43.1 million in Q1 2023.
  • For the 3-year period, Iovance Biotherapeutics' Accumulated Expenses averaged around $67.8 million, with its median value being $69.4 million (2023).
  • In the last 5 years, Iovance Biotherapeutics' Accumulated Expenses surged by 777.01% in 2024 and then skyrocketed by 8241.24% in 2025.
  • Iovance Biotherapeutics' Accumulated Expenses (Quarter) stood at $69.4 million in 2023, then increased by 18.05% to $81.9 million in 2024, then increased by 6.51% to $87.3 million in 2025.
  • Its Accumulated Expenses stands at $87.3 million for Q3 2025, versus $89.1 million for Q2 2025 and $84.7 million for Q1 2025.